How is the way we take care of our health and well-being changing? What technologies lie ahead? Our Human+ Healthcare Dialogues event series brings together the perspectives of those who do research, provide care, and invest.See all eventsHuman+ Healthcare Dialogue 3 – Life Redesigned: September 29, 2026For centuries, we studied biology. Now we use it to build drugs, tissues, and cells. Here are the topics we discussed:The mindset you need to accelerate or fund a biotech startupDavide EderleHead of Innovation at Fondazione Città della Speranza, vice president of ALISEI, the Italian life sciences cluster, and one of the founders of the Italian National Association of Biotechnologists.How international investors assess biotechMaddalena AdornoOperating Partner at BioInnovation Institute and co-founder of Dorian Therapeutics, acquired by Altos Labs.Capital, regulation, and Italy’s National Biotechnology PlanMarica NobileDirector of Assobiotec-Federchimica, the Italian biotech association.How a major pharmaceutical company turns market signals into decisionsGiorgia IegianiCompetitive Intelligence Specialist at Chiesi Farmaceutici.Same lab, opposite business modelsEmiliano BiasiniLeads a lab on rare genetic diseases and co-founded Sibylla Biotech (€23 million raised) and BrightMol.When research becomes a productAnna TampieriSenior Research Director at The National Research Council of Italy, inventor and co-founder of GreenBone Ortho, which produces bone substitutes made from rattan wood.For science to work, it has to be manufacturableMassimiliano CesariniCEO of Biogenera, which develops DNA-based drugs for pediatric cancers, in clinical trials since 2026.Moderator: Antonella Carillo, vice president of the Italian National Association of Biotechnologists.The event is part of European Biotech Week, coordinated and promoted nationwide in Italy by Assobiotec-Federchimica.